GlassScriptPhysician profile
Shine H Kim
NPI 1093968737
$5,300.47
in general payments reported to CMS, 2019-2025
23 companies · $864 in 2025
The $864 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $179 · 2021: $900 · 2022: $1,044 · 2023: $903 · 2024: $1,099 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,855 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,855.08 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $792.01 | 2021-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Janssen Pharmaceuticals, INC | $786.01 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $725.22 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Shionogi INC | $623.58 | 2021-2025 | Fetroja |
| Abbvie INC. | $536.22 | 2021-2025 | |
| Pfizer INC. | $501.39 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $285.14 | 2019-2025 | Eliquis, Camzyos |
| La Jolla Pharmaceutical Company | $168.56 | 2023-2025 | Xerava, Xacduro, Zevtera |
| Abbott Laboratories | $140.76 | 2024 | Optis |
| Gilead Sciences, INC. | $131.29 | 2023-2025 | Yeztugo |
| Mylan Specialty L.P. | $127.76 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.45 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $94.09 | 2021-2022 | |
| Cumberland Pharmaceuticals, INC. | $63.22 | 2022-2025 | Caldolor |
| Fisher Scientific Company L.L.C. | $35.93 | 2023 | Procalcitonin |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $35.70 | 2021 | |
| Smith+Nephew, INC. | $32.62 | 2022-2024 | Collagenase Santyl |
| Allergan, INC. | $23.37 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.87 | 2023 | Lifevest |
| Regeneron Healthcare Solutions, INC. | $20.25 | 2022 | |
| Paratek Pharmaceuticals, INC. | $19.92 | 2021 | |
| Chiesi USA, INC. | $16.95 | 2025 | Cleviprex, Kengreal |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2024 | Andexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shine Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.